Visual and Anatomic Outcomes in nAMD Patients With Subretinal Hemorrhage After Treatment With Faricimab in the TRUCKEE Study - First Time Results of Two-Year Data

Document Type

Conference Proceeding

Publication Date

6-2025

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Faricimab was FDA-approved for nAMD in Jan 2022. Current agents provide benefit to patients but demonstrate declines in visual acuity as treatments continue. Faricimab is the first bispecific agent inhibiting VEGF-A and ANG-2 pathways for the treatment of nAMD and associated subretinal hemorrhage (SRH). This multi-center, retrospective study evaluates the safety and efficacy of faricimab in real-world nAMD patients with SRH.

Methods : This multi-center retrospective study investigates faricimab treatment for nAMD in both treatment-naïve patients and patients switched to faricimab from other anti-VEGF agents. Data collected includes demographics, treatment history, best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of SRH, and presence of subretinal or intraretinal fluid (SRF or IRF). Snellen visual acuity was converted to the Early Treatment Diabetic Retinopathy Study (ETDRS) scoring. Improvements in visual acuity and CST are evaluated as averages. Improvements in SRH and retinal fluid are evaluated as a proportion of patients. Observed and calculated data is reported. Safety is summarized.

Results : A total of 205 eyes across 205 patients were recorded with SRH at time of first faricimab injection. The average age was 80.6 years and 60% of patients were male. Following one faricimab injection, 184 eyes saw a 1.1 letter (p=0.99358) increase, a CST decrease of 39.5μm (p< 0.0001), and resolution rates for SRH, SRF, and IRF of 35%, 39%, and 29%, respectively. Following three faricimab injections, 156 eyes saw a 1.7 letter (p< 0.0001) increase, a CST decrease of 61.2μm (p< 0.0001), and resolution rates for SRH, SRF, and IRF of 75%, 59%, and 50%, respectively. No adverse events have been reported in these patients.

Conclusions : Faricimab has demonstrated efficacy via anatomic and visual parameters and acceptable safety in previously treated patients with subretinal hemorrhages, a demographic not studied in the trials leading to FDA-approval. Future results will continue to investigate the safety and efficacy of faricimab in real-world patients suffering from nAMD-associated SRH. Latest data will be presented at ARVO 2025.

Volume

66

Issue

8

First Page

4106

Comments

Association for Research in Vision and Ophthalmology ARVO Annual Meeting, May 4-8, 2025, Salt Lake City, UT

Last Page

4106

Link to Full Text

Share

COinS